header.html

An official website of the European Union How do you know?      
European Commission logo

handle.jsp

cover
Neutralizing antibodies that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein are among the most promising approaches against COVID-19. A bispecifc IgG1-like molecule (CoV-X2) has been developed on the basis of C121 and C135, two antibodies derived from donors who had recovered from COVID-193. Here we show that CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable spike binding to the cellular receptor of the virus, angiotensin-converting enzyme 2 (ACE2). Furthermore, CoV-X2 neutralizes wild-type SARS-CoV-2 and its variants of concern, as well as escape mutants generated by the parental monoclonal antibodies. We also found that in a mouse model of SARS-CoV-2 infection with lung infammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, the simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecifc antibodies is feasible and effective, and combines the advantages of antibody cocktails with those of single-molecule approaches.
2021-11-16
NATURE PUBLISHING GROUP
JRC123490
0028-0836 (online),   
https://www.nature.com/articles/s41586-021-03461-y,    https://publications.jrc.ec.europa.eu/repository/handle/JRC123490,   
10.1038/s41586-021-03461-y (online),   
NameCountryCityType
Datasets
IDTitlePublic URL
Dataset collections
IDAcronymTitlePublic URL
Scripts / source codes
DescriptionPublic URL
Additional supporting files
File nameDescriptionFile type 

footer.html